Skip to content
Back to explorer
Printable monograph

Alkylator

Melphalan

Alkeran · Mel

Alkylator · approved 1964 · 8 citations · FAERS AKI reporting ROR 2.94 (95% CI 2.73–3.16, 768 AKI reports)

Up to date· through 2025
Deeply sourced8/9 · 7 signals
  • Met: 8 citations
  • Not met: 12+ references
  • Met: Accrued over 10+ years (span: 40y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2025
  • Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

The myeloma workhorse whose high-dose conditioning can quietly drop the serum sodium.

MildAlkylator
Multiple myelomaAutologous stem cell transplant conditioningLight-chain (AL) amyloidosisOvarian cancer; regional perfusion for melanoma

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Reduce dose by kidney function
High-dose conditioning: reduce to 140 mg/m2 in significant renal impairment/dialysis dependence and AL amyloidosis
The atlas summary, paraphrased — not label text. Verbatim label excerpt. Dosing section.
Hemodialysis
Not removed by hemodialysis
Not reliably removed by dialysis, but high-dose conditioning is feasible in dialysis-dependent patients using a reduced 140 mg/m2 dose (full 200 mg/m2 also shown feasible in renal failure).PMID 17075230 (opens PubMed in a new tab)PMID 9816255 (opens PubMed in a new tab)
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: IVRA, Sep 2026. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

Signature lesion

High-dose intravenous melphalan can cause hyponatremia/SIADH; in a small high-dose series most patients showed declining sodium, but this is reported at case/series level rather than as a large quantified rate. Melphalan PK is not adversely affected by renal failure, so transplant in renal impairment is feasible.Source: Greenbaum-Lefkoe et al., Cancer 1985

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Days after high-dose administration.

Distilled from: “Days after high-dose administration.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. SIADH / Hyponatremia#1 · Signatureno population incidence denominator

    SIADH with hyponatremia and inappropriate urinary sodium loss reported after high-dose IV bolus melphalan (both patients at 2 mg/kg; falling serum Na in 7/10 at 1 mg/kg). PMID 3965085 (opens PubMed in a new tab)

  2. Hyponatremia in 12/34 (35%) after high-dose melphalan, coinciding with diarrhea ~day 10-12 (attributed to GI losses, not SIADH).

§03

Kidney injury

Deep diveDrug-induced SIADH: the sodium falls and the tumour takes the blameHyponatremia is the commonest electrolyte disorder in oncology and its commonest explanation is the cancer itself — which is exactly why a drug that impairs free-water excretion can go on being given for months while the sodium is treated as a feature of the disease.

Mechanism of kidney injury

High-dose bolus melphalan can precipitate inappropriate antidiuretic hormone secretion with free-water retention and dilutional hyponatremia; conditioning-related mucositis and diarrhea cause additional volume and sodium disturbances (some hyponatremia is GI-loss rather than true SIADH). Melphalan is partly renally cleared, so impaired kidney function raises systemic and mucosal toxicity and motivates dose reduction (e.g., 200 to 140 mg/m2) in renal failure/amyloidosis.

Clinical presentation

Hyponatremia with inappropriately concentrated urine and ongoing natriuresis (SIADH pattern); in the conditioning setting, accompanying mucositis, diarrhea and volume shifts. Direct tubular nephrotoxicity is not characteristic.

Management

Manage SIADH with fluid restriction and careful, rate-limited sodium correction; treat volume and electrolyte derangements supportively. Hyponatremia typically resolves as the acute effect and mucositis abate.Lesion-level management framework

Risk factors

  • High-dose / bolus IV administration (conditioning)
  • Renal impairment (reduced clearance, greater mucosal toxicity)
  • Concurrent hypotonic fluids
  • Mucositis/diarrhea-related volume loss

Prevention

  • Avoid excess hypotonic fluids
  • Dose-reduce (e.g., 140 mg/m2) and monitor in renal impairment / amyloidosis
Anticancer mechanism· how it treats cancer

Phenylalanine-mustard bifunctional alkylating agent that cross-links DNA. Backbone of multiple myeloma therapy and the standard high-dose conditioning agent before autologous stem cell transplant; also used in light-chain (AL) amyloidosis and (regional perfusion) melanoma.

§04

Clinical depth

Renal dose adjustment

For high-dose conditioning, 140 mg/m2 is commonly used as a conservative dose in significant renal impairment / dialysis dependence and in AL amyloidosis. Melphalan pharmacokinetics are NOT adversely affected by impaired renal function (Tricot), so renal impairment is not itself a barrier to high-dose conditioning; that study nonetheless found renal insufficiency associated with longer fever and hospitalization, and the same group later reported that the more pronounced toxicity of the 200 mg/m2 regimen is why 140 mg/m2 became the standard of care.

Dialyzability & ESKD dosing

Melphalan is short-lived (rapid chemical hydrolysis) so it is not reliably removed by dialysis as a rescue; however, high-dose autotransplant has been performed safely in dialysis-dependent patients using the reduced 140 mg/m2 dose with attention to mucositis.

Differential diagnosis

Euvolemic hyponatremia with concentrated urine and natriuresis points to SIADH; hypovolemic hyponatremia with low urine sodium and clinical volume loss points to mucositis/diarrhea-driven depletion. The distinction changes management (fluid restriction vs cautious repletion).

Monitoring

  • Serum sodium and fluid balance during/after high-dose therapy
  • Mucositis severity and volume status (diarrhea-related hyponatremia)

Key trials & series

  • Greenbaum-Lefkoe Cancer 1985 - original SIADH/hyponatremia description after high-dose IV melphalan
  • Tricot Clin Cancer Res 1996 - PK/toxicity of high-dose melphalan autotransplant in renal failure
  • Sanchorawala Bone Marrow Transplant 2001 - HDM/SCT in AL amyloidosis with renal involvement

Clinical pearls

  • Check sodium after high-dose melphalan - SIADH is the signature renal-electrolyte event, not tubular injury.
  • Renal failure is NOT a contraindication to high-dose melphalan transplant; reduce to 140 mg/m2 and watch mucositis.
  • Not all post-conditioning hyponatremia is SIADH - GI losses from mucositis/diarrhea are a common, differently managed cause.
Where it strikes· nephron segments & injury signatures

Nephron segments

Distal Tubule / Collecting Duct

Fine-tuning of Na, K, Mg, acid & water

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the Alkylator class.

Hematologic

Cytopenias, thrombosis, TMA

  • Myelosuppression; secondary malignancy risk

Neurologic

Neuropathy, encephalopathy, ICANS, PRES

  • Ifosfamide encephalopathy (chloroacetaldehyde)

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

  • High-dose cyclophosphamide cardiotoxicity
§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 1985–2007 · 1 since 2005
201985: 1 citation1986: 1 citation1996: 1 citation2001: 2 citations2003: 1 citation2007: 1 citation1985199020002007

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkSyndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan.Greenbaum-Lefkoe B et al. · Cancer · 1985 · PMID 3965085Original description of SIADH/hyponatremia after high-dose IV melphalan.
  2. 2.L-phenylalanine mustard-dianhydrogalactitol and hyponatremia.Helson L et al. · Pediatr Hematol Oncol · 1986 · PMID 3153241Hyponatremia after high-dose melphalan-containing therapy, here linked to diarrhea.
  3. 3.Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.Tricot G et al. · Clin Cancer Res · 1996 · PMID 9816255Prospective PK/toxicity study giving full 200 mg/m2 melphalan conditioning in renal failure/dialysis: PK unaffected and toxicity acceptable, with the authors concluding renal failure does not require dose reduction — though 140 mg/m2 remains a common conservative choice, especially in AL amyloidosis.
  4. 4.High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.Pineda-Roman M et al. · Contrib Nephrol · 2007 · PMID 17075230Onconephrology review of melphalan dosing on dialysis and dialysis-independence outcomes.
  5. 5.An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.Sanchorawala V et al. · Bone Marrow Transplant · 2001 · PMID 11704785HDM/SCT in AL amyloidosis with renal/nephrotic involvement and dose adjustment.
  6. 6.Advances in biology and therapy of multiple myeloma.Barille-Nion S et al. · Hematology Am Soc Hematol Educ Program · 2003 · PMID 14633785Reviews melphalan dose reduction (200 to 140 mg/m2) in renal failure/amyloidosis.
  7. 7.Anticancer drug-induced kidney disorders.Kintzel PE · Drug Saf · 2001 · PMID 11219485General onconephrology context for alkylator electrolyte and renal effects.
Case reports — ranked by strength· 1

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

FDA label — boxed warning & renal dosing· boxed warning · renal impairment

Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: SEVERE BONE MARROW SUPPRESSION, HYPERSENSITIVITY and LEUKEMOGENICITY Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous melphalan to oral melphalan have shown more myelosuppression with the intravenous formulation. Monitor hematologic laboratory parameters [see Warnings and Precautions ( 5.1 )] . Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the intravenous formulation of melphalan. Discontinue treatment with IVRA for serious hypersensitivity reactions [see Warnings and Precautions ( 5.4 )] . Melphalan produces chromosomal aberrations in vitro and in vivo . IVRA should be considered potentially leukemogenic in humans [see Warnings and Precautions ( 5.5 )]. WARNING: SEVERE BONE MARROW SUPPRESSION, HYPERSENSITIVITY and LEUKEMOGENICITY See full prescribing information for complete boxed warning. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous melphalan to oral melphalan have shown more myelosuppression with the intravenous formulation. Monitor hematologic laboratory parameters ( 5.1 ). Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the intravenous formulation of melphalan. Discontinue treatment with IVRA for…

Renal impairment — from the label

Consider a dosage reduction in patients with renal insufficiency receiving intravenous IVRA [see Dosage and Administration ( 2.2 )] . In one trial, increased bone marrow suppression was observed in patients with elevated BUN [see Clinical Pharmacology ( 12.3 )] .

Kidney rows of the label's dosage tables

From the Hepzato Kit label (Jun 2026) · DailyMed

No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 25,290 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS reported renal phenotypes· 8 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.

What reporting says about this profile's documented lesions

  • Electrolyte Disturbancecorroborated · ROR 1.90 — on the terms that name the lesion (ROR 1.75 · IC025 0.26)
  • SIADH / Hyponatremiacorroborated · ROR 1.75 — on the terms that name the lesion (ROR 4.09 · IC025 1.58)
Thrombotic Microangiopathy
ROR 25.6795% CI 23.48–28.06· 512 reports· IC025 4.44
Hemorrhagic Cystitis
ROR 3.0495% CI 2.69–3.43· 267 reports· IC025 1.40
Fanconi Syndrome
ROR 2.8695% CI 1.82–4.48· 19 reports· IC025 0.72
Acute Interstitial Nephritis
ROR 2.3895% CI 1.86–3.04· 65 reports· IC025 0.86· 10 of 65 reports look like one case filed repeatedly; without them ROR 2.01 (95% CI 1.54–2.62)
Glomerular Injury / Proteinuria
ROR 2.2295% CI 1.79–2.75· 84 reports· IC025 0.81
Electrolyte Disturbance
ROR 1.9095% CI 1.74–2.08· 480 reports· IC025 0.78
Acute Tubular Necrosis
ROR 1.8095% CI 1.21–2.69· 24 reports· IC025 0.19
SIADH / Hyponatremia
ROR 1.7595% CI 1.52–2.02· 186 reports· IC025 0.58
FAERS outcomes & reporting trend· 23.7% of reports w/ death · 29.1% w/ hospitalization
23.7%

Reported with a death outcome

6,005 of 25,290 reports

29.1%

Reported with hospitalization

7,348 of 25,290 reports

Reports per year

  • 2015: 1,166 reports
  • 2016: 1,187 reports
  • 2017: 1,257 reports
  • 2018: 1,710 reports
  • 2019: 1,881 reports
  • 2020: 1,915 reports
  • 2021: 1,977 reports
  • 2022: 1,577 reports
  • 2023: 1,986 reports
  • 2024: 1,770 reports
  • 2025: 1,289 reports
  • 2026: 1,041 reports

Reports received per year, 2015–2026 · most recent year is partial · 6,534 of the 25,290 reports predate 2015 and are not drawn.

FAERS adverse-event signal — all organ systems· 7 systems · 25,290 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 2.9495% CI 2.73–3.16· 768 AKI reports· IC025 1.42·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.
Renal & urinary
Acute Kidney Injury592Renal Failure489
Blood & lymphatic
Febrile Neutropenia1,356Neutropenia1,244Thrombocytopenia1,148Anaemia751Pancytopenia690
Immune / infection
Pneumonia1,162Sepsis909Infection774Acute Graft Versus Host Disease580Graft Versus Host Disease510
Gastrointestinal
Mucosal Inflammation1,281Diarrhoea1,079Nausea603
General / constitutional
Pyrexia1,185
Nervous system
Neuropathy Peripheral755
Hepatobiliary
Venoocclusive Liver Disease554
Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Melphalan sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Temozolomide

Temodar · Alkylator

Profile

Occasional SIADH; generally renally well tolerated.

SIADHLYTE
Mild#1 · 100% phenotype match

Chlorambucil

Leukeran · Alkylating agent (nitrogen mustard)

Profile

Minimal direct nephrotoxicity; rare drug-associated SIADH/hyponatremia is the kidney-relevant signal.

SIADHLYTE
Mild#2 · 97% phenotype match

Vinblastine

Velban · Vinca alkaloid

Profile

SIADH and rare Raynaud/vascular events.

SIADHLYTE
Mild#3 · 89% phenotype match

Vincristine

Oncovin · Vinca alkaloid

Profile

SIADH → hyponatremia.

SIADHLYTE
Mild#4 · 89% phenotype match

Vinorelbine

Navelbine · Vinca alkaloid

Profile

SIADH reports.

SIADHLYTE
Mild#5 · 89% phenotype match

Vismodegib

Erivedge · Hedgehog (SMO) inhibitor

Profile

Muscle spasms; hyponatremia reported.

SIADHLYTE
Mild#6 · 87% phenotype match
Compare Melphalan with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Alkylating agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.

  1. 1Altretamine (hexamethylmelamine)FAERS n/aMild
  2. 1DacarbazineMild
  3. 1EstramustineMild
  4. 4ChlorambucilMild
  5. 5ThiotepaFAERS AKIMild
  6. 6CyclophosphamideFAERS AKIMild
  7. 6Melphalan· this agentFAERS AKIMild
  8. 6TemozolomideFAERS AKIMild
  9. 9LurbinectedinFAERS AKIMild
  10. 10Lomustine (CCNU)Moderate
  11. 11MechlorethamineModerate
  12. 11Melphalan flufenamide (melflufen)Moderate
  13. 13FotemustineModerate
  14. 13Nimustine (ACNU)Moderate
  15. 15BusulfanFAERS AKIModerate
  16. 16Carmustine (BCNU)FAERS AKIModerate
  17. 16ProcarbazineFAERS AKIModerate
  18. 16TrabectedinFAERS AKIModerate
  19. 19BendamustineFAERS AKIModerate
  20. 20StreptozocinFAERS AKISevere
  21. 21IfosfamideFAERS AKISevere

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Melphalan’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Melphalan; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

  1. Dimopoulos, Meletios A — their work on Melphalan, on PubMed (opens in a new tab)6 papers · 959 citesPMID 30819926 (opens PubMed in a new tab)PMID 27646819 (opens PubMed in a new tab)PMID 26976420 (opens PubMed in a new tab)
  2. Goldschmidt, Hartmut — their work on Melphalan, on PubMed (opens in a new tab)6 papers · 755 citesPMID 36328040 (opens PubMed in a new tab)PMID 34341985 (opens PubMed in a new tab)PMID 26976420 (opens PubMed in a new tab)
  3. Leung, Nelson — their work on Melphalan, on PubMed (opens in a new tab)10 papers · 864 citesPMID 35522968 (opens PubMed in a new tab)PMID 29249234 (opens PubMed in a new tab)PMID 26976420 (opens PubMed in a new tab)
  4. Terpos, Evangelos — their work on Melphalan, on PubMed (opens in a new tab)5 papers · 1,049 citesPMID 38937492 (opens PubMed in a new tab)PMID 27646819 (opens PubMed in a new tab)PMID 26976420 (opens PubMed in a new tab)
  5. Gertz, Morie A — their work on Melphalan, on PubMed (opens in a new tab)7 papers · 788 citesPMID 25377159 (opens PubMed in a new tab)PMID 18178602 (opens PubMed in a new tab)PMID 17699449 (opens PubMed in a new tab)

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 175 clinical records among the 300 most-relevant of 398 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.